Morning Overview on MSN
The biggest GLP-1 drug mistake, and how to avoid it
The FDA has spent much of 2025 issuing warnings about a single, recurring problem with GLP-1 weight loss drugs: patients and ...
The FDA has approved a higher 7.2 mg dose of Novo Nordisk’s Wegovy (Wegovy HD) for chronic weight management in adults with ...
Data from the phase 3b STEP UP trial demonstrate that the 7.2 mg semaglutide dose provides superior weight reduction compared ...
What if treating obesity could be as easy as popping an effective pill? That's a notion that has long fueled hope for many of the more than 40% of Americans who are considered obese — and fueled ...
The high-dose Wegovy helped patients with obesity lose an average 20.7% of their weight after 72 weeks in a phase three trial.
Americans can now purchase the starter dose of blockbuster weight-loss drug Wegovy as a pill, drug maker Novo Nordisk announced Monday. Other strengths will be available as pills by the end of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results